DPP-1 Inhibitors Aim to Reduce Bronchiectasis Flare-Ups
A new class of drugs offers a disease-based approach to managing non-cystic fibrosis bronchiectasis by targeting airway inflammation.
A new class of drugs offers a disease-based approach to managing non-cystic fibrosis bronchiectasis by targeting airway inflammation.
Testing via oral swabs identified hidden systemic inflammation in patients with primary ciliary dyskinesia even when they were not experiencing acute illness.
A study of over 1.1 million American adults with asthma found that Black, Hispanic, and Asian patients use ICS, LABA and LAMA inhalers less frequently than white patients.
A new study shows tezepelumab (Tezspire) reduced asthma exacerbations by 70% across all patient subgroups, including smokers and those with comorbid conditions.
A newly discovered biological process protects liver cells from protein buildup in patients with alpha-1-antitrypsin deficiency.
New research indicates that baseline lung health is a stronger predictor of SARS-CoV-2 outcomes in cystic fibrosis transplantation patients than the time elapsed since transplantation.
Data from clinical trials investigating treatments for pulmonary hypertension and pulmonary fibrosis will be highlighted at ATS 2026.
New studies suggest that airway and breathing failures are the primary causes of death in childhood food anaphylaxis, requiring a shift in emergency management protocols.
Pediatric pulmonary rehab programs enhance exercise capacity, strength, and quality of life even when lung function measurements remain stable.